According to the Hong Kong Stock Exchange announcement, XUNFEIHEALTH (02506) released its interim results for 2025 on August 20. In the first half of the year, the company achieved revenue of 298.6 million yuan, up 30% year-on-year, with gross profit of 153.9 million yuan, up 27% year-on-year. The gross margin remained at a high level of 51.5%, with profitability and growth continuing to lead the industry. In terms of technological innovation, the company's R&D investment in the first half of 2025 reached 134 million yuan, accounting for 45% of revenue, continuously strengthening its technological leadership advantages. As the industry's only large model trained on fully domestically-produced computing power, the Spark Medical AI Model V2.5 International Edition was released in June and topped the Medbench rankings with high scores. Meanwhile, its comprehensive diagnostic capabilities in cardiology, pediatrics, and respiratory medicine reached the level of attending physicians at top-tier hospitals. Additionally, the company launched the "Deep Reasoning and Thinking Large Model" Spark Medical AI Model X1 in March 2025, which was upgraded in July, continuing to maintain significant industry leadership in general medical tasks such as general practice-assisted diagnosis, health examination report interpretation, health consultation, and medical guidance services.